Various preclinical and clinical studies have already identified a relationship between PCSK9 and NAFLD, suggesting that bloodstream PCSK9 is able to limit lipid uptake and their subsequent accumulation in the liver. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.